Nervgen Pharma Corp Stock Number Of Shares Shorted

NGEN Stock  CAD 2.90  0.10  3.33%   
NervGen Pharma Corp fundamentals help investors to digest information that contributes to NervGen Pharma's financial success or failures. It also enables traders to predict the movement of NervGen Stock. The fundamental analysis module provides a way to measure NervGen Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NervGen Pharma stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

NervGen Pharma Corp Company Number Of Shares Shorted Analysis

NervGen Pharma's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Shares Shorted

 = 

Shorted by Public

+

by Institutions

More About Number Of Shares Shorted | All Equity Analysis

Current NervGen Pharma Number Of Shares Shorted

    
  199.54 K  
Most of NervGen Pharma's fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NervGen Pharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

NervGen Number Of Shares Shorted Driver Correlations

Understanding the fundamental principles of building solid financial models for NervGen Pharma is extremely important. It helps to project a fair market value of NervGen Stock properly, considering its historical fundamentals such as Number Of Shares Shorted. Since NervGen Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NervGen Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NervGen Pharma's interrelated accounts and indicators.
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Competition

Based on the recorded statements, NervGen Pharma Corp has 199.54 K of outstending shares currently sold short by investors. This is 93.76% lower than that of the Biotechnology sector and 96.09% lower than that of the Health Care industry. The number of shares shorted for all Canada stocks is 95.76% higher than that of the company.

NervGen Number Of Shares Shorted Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NervGen Pharma's direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NervGen Pharma could also be used in its relative valuation, which is a method of valuing NervGen Pharma by comparing valuation metrics of similar companies.
NervGen Pharma is currently under evaluation in number of shares shorted category among its peers.

NervGen Pharma Current Valuation Drivers

We derive many important indicators used in calculating different scores of NervGen Pharma from analyzing NervGen Pharma's financial statements. These drivers represent accounts that assess NervGen Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of NervGen Pharma's important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Enterprise Value44.9M46.7M66.0M90.3M81.3M47.2M

NervGen Fundamentals

About NervGen Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze NervGen Pharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NervGen Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NervGen Pharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for NervGen Stock Analysis

When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.